Related Experiment Video
Updated: Jan 7, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
Human epidermal growth factor receptor 2 and androgen receptor expression in invasive breast carcinoma of no special
Manxiu Li1, Liting Jin, Jun Shao
1Department of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, Wuhan, Hubei, China.
Background:
Invasive breast carcinoma of no special type with medullary pattern (BCNST-MP) is a rare subtype of breast cancer. Previous studies have reported the high prevalence of the triple-negative phenotype in BCNST-MP. This study aimed to investigate the prevalence of human epidermal growth factor receptor 2 (HER2)-low and androgen receptor (AR) expression in this distinct breast cancer subtype.
Methods:
We conducted a retrospective analysis of breast cancer patients diagnosed at our center between 2019 and 2024. Medical records and pathology reports were reviewed to assess the clinicopathological characteristics of BCNST-MP.
Results:
A total of 45 patients with BCNST-MP met the inclusion criteria. The median age at diagnosis was 51 years. Most tumors (93.3%) measured ≤5 cm, and axillary lymph node metastasis was observed in 26.7% of cases. Eighty percent of the patients were estrogen receptor (ER)-negative, 84% were progesterone receptor (PR)-negative, and 75.6% were AR-negative. Regarding the HER2 status, 15.6% were HER2-positive, 33.3% exhibited HER2-low expression, and 51.1% had HER2-zero expression. With a median follow-up duration of 26 months, only one patient-a 30-year-old with triple-negative breast cancer-developed distant metastasis. An 82-year-old died of a cerebrovascular accident.
Conclusions:
Our findings suggest that BCNST-MP tumors are rarely larger than 5 cm and are frequently lymph node-negative. Most patients were negative for ER, PR, AR, and HER2. Notably, HER2-low expression was observed in approximately 30% of cases, suggesting therapeutic implications.
More Related Videos
Related Concept Videos
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

